Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
Plasma insulin-like growth factor-I (IGF-I) was measured in breast cancer patients before and during treatment with tamoxifen, goserelin or aminoglutethimide. 24 out of 27 postmenopausal women treated with tamoxifen 20 or 30 mg daily experienced a decrease in plasma IGF-I levels (mean levels before treatment 14.8 nM, during treatment 10.2 nM, P less than 0.001). In 8 out of 12 premenopausal breast cancer patients there was a reduction in plasma IGF-I during treatment with goserelin (mean levels before treatment 23.3 nM, during treatment 19.4 nM, P = 0.052). Contrary, 15 out of 17 postmenopausal women treated with the aromatase inhibitor aminoglutethimide had an increase in plasma IGF-I level (mean level before treatment 17.0 nM, during treatment 21.1 nM, P less than 0.01). These preliminary results indicate that different forms of endocrine treatment of breast cancer may influence plasma IGF-I levels in different directions.
Lien
E A
EA
Medical Department, Haukeland University Hospital, Bergen, Norway.
Johannessen
D C
DC
Aakvaag
A
A
Lønning
P E
PE
D000616:Aminoglutethimide / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy*; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003348:Cortisone / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D017273:Goserelin; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008593:Menopause; D008875:Middle Aged; D013629:Tamoxifen / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013629:Tamoxifen; D017273:Goserelin; D000616:Aminoglutethimide; D007334:Insulin-Like Growth Factor I; D002064:Buserelin; D003348:Cortisone